

Timothy Vartanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2141396/publications.pdf>

Version: 2024-02-01

22
papers

740
citations

687363

13
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

1183
citing authors

#	ARTICLE	IF	CITATIONS
1	Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. <i>Nature</i> , 2021, 600, 707-712.	27.8	35
2	A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis. <i>Molecular Imaging and Biology</i> , 2020, 22, 1600-1608.	2.6	5
3	Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions. <i>Journal of Neuroimaging</i> , 2020, 30, 537-543.	2.0	7
4	Black African and Latino/a identity correlates with increased plasmablasts in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	11
5	In vivo Blood-brain Barrier Permeability Assays Using Clostridium perfringens Epsilon Toxin. <i>Bio-protocol</i> , 2020, 10, e3709.	0.4	2
6	Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL. <i>PLoS Pathogens</i> , 2019, 15, e1008014.	4.7	21
7	Clostridium perfringens Epsilon Toxin Compromises the Blood-Brain Barrier in a Humanized Zebrafish Model. <i>IScience</i> , 2019, 15, 39-54.	4.1	10
8	Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 540-542.	3.0	13
9	Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 553-554.	3.0	1
10	A Novel Panel of Rabbit Monoclonal Antibodies and Their Diverse Applications Including Inhibition of Clostridium perfringens Epsilon Toxin Oligomerization. <i>Antibodies</i> , 2018, 7, 37.	2.5	8
11	Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 27-33.	2.0	25
12	Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans. <i>Journal of Neuroimaging</i> , 2017, 27, 333-338.	2.0	17
13	Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 11.	3.9	51
14	A study of patients with aggressive multiple sclerosis at disease onset. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1907-1912.	2.2	11
15	Relapses in multiple sclerosis: Relationship to disability. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 10-20.	2.0	36
16	Measuring longitudinal myelin water fraction in new multiple sclerosis lesions. <i>NeuroImage: Clinical</i> , 2015, 9, 369-375.	2.7	58
17	Re-evaluating the treatment of acute optic neuritis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 799-808.	1.9	29
18	The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens Îµ-Toxin. <i>PLoS Pathogens</i> , 2015, 11, e1004896.	4.7	69

#	ARTICLE	IF	CITATIONS
19	Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination. MBio, 2015, 6, e02513.	4.1	71
20	Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease. PLoS ONE, 2013, 8, e76359.	2.5	169
21	Carbon Monoxide Suppresses Membrane Expression of TLR4 via Myeloid Differentiation Factor-2 in \hat{I}^2 TC3 Cells. Journal of Immunology, 2010, 185, 2134-2139.	0.8	24
22	Nna1 Mediates Purkinje Cell Dendritic Development via Lysyl Oxidase Propeptide and NF- \hat{I}^{B} Signaling. Neuron, 2010, 68, 45-60.	8.1	67